第 1 到 23 筆結果,共 23 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2024 | Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study | Chang, Gee-Chen; Chiu, Chao-Hua; CHONG-JEN YU ; YEUN-CHUNG CHANG ; Chang, Ya-Hsuan; Hsu, Kuo-Hsuan; Wu, Yu-Chung; CHIH-YI CHEN ; Hsu, Hsian-He; Wu, Ming-Ting; Yang, Cheng-Ta; Chong, Inn-Wen; Lin, Yu-Ching; Hsia, Te-Chun; Lin, Meng-Chih; Su, Wu-Chou; Lin, Chih-Bin; Lee, Kang-Yun; Wei, Yu-Feng; Lan, Gong-Yau; Chan, Wing P; Wang, Kao-Lun; Wu, Mei-Han; Tsai, Hao-Hung; Chian, Chih-Feng; Lai, Ruay-Sheng; JIN-YUAN SHIH ; Wang, Chi-Liang; Hsu, Jui-Sheng; Chen, Kun-Chieh; Chen, Chun-Ku; Hsia, Jiun-Yi; Peng, Chung-Kan; Tang, En-Kuei; CHIA-LIN HSU ; Chou, Teh-Ying; Shen, Wei-Chih; Tsai, Ying-Huang; Tsai, Chun-Ming; Chen, Yuh-Min; Lee, Yu-Chin; Chen, Hsuan-Yu; SUNG-LIANG YU ; Chen, Chien-Jen; Wan, Yung-Liang; Hsiung, Chao Agnes; PAN-CHYR YANG | The Lancet. Respiratory medicine | 6 | ||
2 | 2024 | Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib | Wu, Jia-Jun; Tseng, Jeng-Sen; Zheng, Zhe-Rong; Chu, Cheng-Hsiang; Chen, Kun-Chieh; MONG-WEI LIN ; Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Yang, Tsung-Ying; SUNG-LIANG YU ; JIN-SHING CHEN ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 0 | ||
3 | 2023 | Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages | Ho, Hao; SUNG-LIANG YU ; Chen, Hsuan-Yu; Yuan, Shin-Sheng; KANG-YI SU ; Hsu, Yi-Chiung; Hsu, Chung-Ping; Chuang, Cheng-Yen; Chang, Ya-Hsuan; Li, Yu-Cheng; Cheng, Chiou-Ling; Chang, Gee-Chen; PAN-CHYR YANG ; Li, Ker-Chau | Lung cancer (Amsterdam, Netherlands) | 0 | 0 | |
4 | 2023 | Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer | Wang, Chi-Liang; Hsu, Kuo-Hsuan; Chang, Ya-Hsuan; CHAO-CHI HO ; CHUN-JU CHIANG ; Chen, Kun-Chieh; Cheung, Yun-Chung; Huang, Pei-Ching; Chen, Yu-Ruei; Chen, Chih-Yi ; Hsu, Chung-Ping; Hsia, Jiun-Yi; Chen, Hsuan-Yu; Yang, Shi-Yi; Li, Yao-Jen; Yang, Tsung-Ying; Tseng, Jeng-Sen; Chuang, Cheng-Yen; Hsiung, Chao A; Chen, Yuh-Min; Huang, Ming-Shyan; CHONG-JEN YU ; KUAN-YU CHEN ; Su, Wu-Chou; Chen, Jeremy J W; SUNG-LIANG YU ; Chen, Chien-Jen; PAN-CHYR YANG ; Tsai, Ying-Huang; Chang, Gee-Chen | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2 | 0 | |
5 | 2022 | Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma | Chi-ya Shen; Chang, Wen-Hsin; Chen, Yi-Ju; Weng, Chia-Wei; Regmi, Prabha; Kier, Mickiela K K; KANG-YI SU ; Chang, Gee-Chen; JIN-SHING CHEN ; Chen, Yu-Ju; SUNG-LIANG YU | Journal of proteome research | 4 | 0 | |
6 | 2022 | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 0 | 0 | |
7 | 2022 | Reduced symmetric dimethylation stabilizes vimentin and promotes metastasis in MTAP-deficient lung cancer | Chang, Wen-Hsin; Chen, Yi-Ju; Hsiao, Yi-Jing; Chiang, Ching-Cheng; Wang, Chia-Yu; Chang, Ya-Ling; Hong, Qi-Sheng; Lin, Chien-Yu; Lin, Shr-Uen; Chang, Gee-Chen; Chen, Hsuan-Yu; Chen, Yu-Ju; Chen, Ching-Hsien; PAN-CHYR YANG ; SUNG-LIANG YU | EMBO reports | 4 | 5 | |
8 | 2022 | Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant) | Wu, Jia-Jun; Lee, Po-Hsin; Zheng, Zhe-Rong; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Yang, Tsung-Ying; SUNG-LIANG YU ; Chen, Kun-Chieh; Chang, Gee-Chen | Medicine | 0 | 0 | |
9 | 2022 | Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid | Liao, Pei-Ya; Ou, Wei-Fan; KANG-YI SU ; Sun, Ming-Hsi; Huang, Chih-Mei; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; SUNG-LIANG YU ; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | Cancers | 0 | 0 | |
10 | 2022 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 7 | 7 | |
11 | 2022 | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Cancer research and treatment | 9 | 6 | |
12 | 2022 | Various impacts of driver mutations on the PD-L1 expression of NSCLC | Chu, Cheng-Hsiang; Huang, Yen-Hsiang; Lee, Po-Hsin; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | PloS one | 3 | 1 | |
13 | 2022 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen | Scientific reports | 11 | 9 | |
14 | 2021 | Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 0 | 0 | |
15 | 2021 | The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 9 | 9 | |
16 | 2021 | The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study | Huang, Yen-Hsiang; Hung, Jen-Yu; Ko, How-Wen; Su, Po-Lan; Lai, Chun-Liang; Chang, Huang-Chih; Hsia, Te-Chun; Lin, Sheng-Hao; Wu, Kuan-Li; Yang, Cheng-Ta; Su, Wu-Chou; Chu, Yi-Chun; Wang, Chin-Chou; WEI-YU LIAO ; YEN-TING LIN ; Lin, Ching-Hsiung; Lin, Meng-Chih; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Lee, Mei-Hsuan; SUNG-LIANG YU ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 3 | 2 | |
17 | 2021 | MITF functions as a tumor suppressor in non-small cell lung cancer beyond the canonically oncogenic role | Hsiao, Yi-Jing; Chang, Wen-Hsin; Chen, Hsuan-Yu; Hsu, Yin-Chen; Chiu, Su-Chin; Chiang, Ching-Cheng; Chang, Gee-Chen; Chen, Yi-Ju; Wang, Chia-Yu; Chen, Yan-Ming; Lin, Chien-Yu; Chen, Yu-Ju; PAN-CHYR YANG ; Chen, Jeremy J W; SUNG-LIANG YU | Aging | 6 | 0 | |
18 | 2021 | Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients | Hsu, Kuo-Hsuan; Huang, Jing-Wen; Tseng, Jeng-Sen; Chen, Kuan-Wen; Weng, Yih-Chyang; SUNG-LIANG YU ; Yang, Tsung-Ying; Huang, Yen-Hsiang; Chen, Jeremy J W; Chen, Kun-Chieh; Chang, Gee-Chen | OncoTargets and therapy | 6 | 6 | |
19 | 2021 | Genome-wide epigenetic landscape of lung adenocarcinoma links HOXB9 DNA methylation to intrinsic EGFR-TKI resistance and heterogeneous responses | SU, SHENG-FANG ; Liu, Chia-Hsin; Cheng, Chiou-Ling; CHAO-CHI HO ; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; HUEI-WEN CHEN ; Chang, Gee-Chen; SUNG-LIANG YU ; Li, Ker-Chau | JCO Precision Oncology | 9 | 6 | |
20 | 2021 | Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment | Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Zheng, Zhe-Rong; Yang, Tsung-Ying; Chen, Kun-Chieh; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Chang, Gee-Chen | Oncology | 9 | 9 | |
21 | 2020 | Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression | Chen, Yi-Ju; Roumeliotis, Theodoros I; Chang, Ya-Hsuan; Chen, Ching-Tai; Han, Chia-Li; MIAO-HSIA LIN ; HUEI-WEN CHEN ; Chang, Gee-Chen; YIH-LEONG CHANG ; CHEN-TU WU ; MONG-WEI LIN ; MIN-SHU HSIEH ; Wang, Yu-Tai; Chen, Yet-Ran; Jonassen, Inge; Ghavidel, Fatemeh Zamanzad; Lin, Ze-Shiang; Lin, Kuen-Tyng; Chen, Ching-Wen; Sheu, Pei-Yuan; Hung, Chen-Ting; Huang, Ke-Chieh; Yang, Hao-Chin; Lin, Pei-Yi; Yen, Ta-Chi; Lin, Yi-Wei; Wang, Jen-Hung; Raghav, Lovely; Lin, Chien-Yu; Chen, Yan-Si; Wu, Pei-Shan; Lai, Chi-Ting; Weng, Shao-Hsing; KANG-YI SU ; Chang, Wei-Hung; Tsai, Pang-Yan; Robles, Ana I; Rodriguez, Henry; Hsiao, Yi-Jing; Chang, Wen-Hsin; Sung, Ting-Yi; JIN-SHING CHEN ; SUNG-LIANG YU ; Choudhary, Jyoti S; Chen, Hsuan-Yu; PAN-CHYR YANG ; Chen, Yu-Ju | Cell | 154 | 134 | |
22 | 2020 | ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients | Chang, Gee-Chen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen | Scientific reports | 26 | 20 | |
23 | 2018 | The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Chen, Kun-Chieh; Hsu, Chia-Hung; KANG-YI SU ; Chen, Jeremy J W; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang, Tsung-Ying; Chang, Gee-Chen | Cancer Research and Treatment | 47 | 45 |